Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology Inc. (ACTC)

Add ACTC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 10/23/2014 12:05:50 AM - Followers: 645 - Board type: Free - Posts Today: 3

Advanced Cell Technology, Inc. (ACTC)




Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662


Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.

Dr. Lanza explains some of the technology we are pursuing:

For more information visit



Share Structure as of November 30, 2011:

Outstanding Shares

Reserved Shares

Authorized and Unreserved Shares



Authorized Preferred Shares



The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.


Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%


* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.

Media Relations

Bill Douglass
Gotham Communications, LLC
bill [at] gothamcomm [dot] com


Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
ACTC News: Quarterly Report (10-q) 05/08/2014 04:41:06 PM
ACTC News: Amended Annual Report (10-k/a) 04/29/2014 04:36:14 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#75441   sharpei 10/23/14 12:05:48 AM
#75440   farviewhill: Thank you. I appreciate your sharpei 10/23/14 12:05:45 AM
#75439   I am not sure I get that as elysse1kittycat 10/23/14 12:01:40 AM
#75438   $ACTC lasers, well said. chuckanutman 10/22/14 11:35:00 PM
#75437   Even though I lost a bundle on actc homeslice10 10/22/14 11:34:05 PM
#75436   It would be a severe blow to keep elllk 10/22/14 11:27:16 PM
#75435   It would be a severe blow to keep elllk 10/22/14 11:27:14 PM
#75434   I do hope those rapid fire PR's picked Gastrodamas 10/22/14 11:24:48 PM
#75433   Sharpei, from your observations as a chartist, how farviewhill 10/22/14 11:16:54 PM
#75432   Once again its close to Wotton awarded share Gastrodamas 10/22/14 11:01:23 PM
#75431   If the irate shareholders got through the bodyguards, elysse1kittycat 10/22/14 10:51:22 PM
#75430   Does this sound good to anyone? chuckanutman 10/22/14 10:48:17 PM
#75429   He might need a couple body guards lol,, fulleroots 10/22/14 10:42:47 PM
#75428   Not to make light of this but can elysse1kittycat 10/22/14 10:27:13 PM
#75427   Smokey: The chart appears to show a sharpei 10/22/14 10:25:43 PM
#75426   ACTC Quote: "Now, we have follow-up that extends chuckanutman 10/22/14 10:17:48 PM
#75424   ACTC Advanced Cell Technology Sharing from Andy Blidy's share: chuckanutman 10/22/14 09:23:45 PM
#75423   Just a statement of fact sorry if it smokey 10/22/14 09:04:35 PM
#75422   any one want to question my motives go fulleroots 10/22/14 09:02:03 PM
#75420   i wouldn't believe anything these actc guys say, fulleroots 10/22/14 08:58:08 PM
#75419   i really wonder if ACTC will even be fulleroots 10/22/14 08:46:21 PM
#75418   Personally I wish that all if any possible elysse1kittycat 10/22/14 05:47:59 PM
#75417   Good posts today from you, appreciate your insight Auger08 10/22/14 05:44:03 PM
#75416   Good point, but imo, not a concern at farviewhill 10/22/14 05:30:26 PM
#75415   I will be a buyer so it has homeslice10 10/22/14 05:20:54 PM
#75414   Lets just hope that this doesn't get below smokey 10/22/14 04:58:22 PM
#75413   Excellent response and real insight into the lack farviewhill 10/22/14 03:54:52 PM
#75410   Wopsal101 Dr. Rose is no friend of $ACTC lasers 10/22/14 01:22:19 PM
#75409   Lincoln is absorbing it for now homeslice10 10/22/14 01:16:11 PM
#75408   At 20/25 you are at line 7, which lasers 10/22/14 01:14:39 PM
#75407   Volume is struggling and will continue to struggle.Their fulleroots 10/22/14 01:07:21 PM
#75406   Lasers, The article posted on FFB website states that Wopsal101 10/22/14 01:07:08 PM
#75404   I could lose big time but I'm betting homeslice10 10/22/14 12:40:27 PM
#75403   Everyone.. I am also sick of the daily guy3 10/22/14 12:39:17 PM
#75402   You are right. It is impossible that those SMD2014 10/22/14 12:11:00 PM
#75401   Art 2426. I have been diagnosed with SMD2014 10/22/14 12:04:48 PM
#75400   WOW, I see what you are saying that art2426 10/22/14 11:43:56 AM
#75399   Would not likely apply to better vision persons lasers 10/22/14 11:43:42 AM
#75398   ACTC is helping wonderful people in need. chuckanutman 10/22/14 11:25:01 AM
#75397   That in itself is disgusting and needs to elysse1kittycat 10/22/14 11:23:29 AM
#75396   Then either staff the SEC properly or get elysse1kittycat 10/22/14 11:16:11 AM
#75395   SEC advice is uplist ASAP. The SEC simply lasers 10/22/14 10:56:24 AM
#75394   oh and a history of integrity , thats fulleroots 10/22/14 10:54:41 AM
#75393   The MMs OTC have a lucrative $multi-bil business lasers 10/22/14 10:53:48 AM
#75392   in my opinion it will be worse once fulleroots 10/22/14 10:50:21 AM
#75391   It is truly sad that people in a elysse1kittycat 10/22/14 10:42:54 AM
#75390   OTC MMs do it to all equities to lasers 10/22/14 10:33:41 AM
#75389   Foundation Fighting Blindness: Since when FDA needs improvement SMD2014 10/22/14 10:33:25 AM
#75388   $ACTC has 50 mil Preferred Shares just waiting lasers 10/22/14 10:29:44 AM
#75387   ACTC makes itself a easy target of manipulation fulleroots 10/22/14 10:29:11 AM